JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 80 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.45 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $166,870 | -37.5% | 90,200 | +182.3% | 0.01% | -33.3% |
| Q4 2021 | $267,000 | +12.7% | 31,952 | 0.0% | 0.01% | +12.5% |
| Q3 2021 | $237,000 | +9.2% | 31,952 | 0.0% | 0.01% | +14.3% |
| Q2 2021 | $217,000 | +27.6% | 31,952 | +93.0% | 0.01% | +16.7% |
| Q1 2021 | $170,000 | +56.0% | 16,552 | +6.4% | 0.01% | +20.0% |
| Q4 2020 | $109,000 | -9.2% | 15,552 | +6.1% | 0.01% | -16.7% |
| Q3 2020 | $120,000 | +18.8% | 14,652 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $101,000 | +44.3% | 14,652 | 0.0% | 0.01% | +20.0% |
| Q1 2020 | $70,000 | -45.3% | 14,652 | 0.0% | 0.01% | -28.6% |
| Q4 2019 | $128,000 | +68.4% | 14,652 | -35.7% | 0.01% | +40.0% |
| Q3 2019 | $76,000 | -32.7% | 22,800 | 0.0% | 0.01% | -28.6% |
| Q2 2019 | $113,000 | +22.8% | 22,800 | +54.1% | 0.01% | +16.7% |
| Q1 2019 | $92,000 | – | 14,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 1,347,829 | $4,084,000 | 88.46% |
| Ally Bridge Group (NY) LLC | 550,000 | $1,667,000 | 1.52% |
| TRV GP III, LLC | 1,148,780 | $3,481,000 | 1.42% |
| Deep Track Capital, LP | 4,259,653 | $12,907,000 | 0.85% |
| COWEN AND COMPANY, LLC | 2,843,149 | $8,615,000 | 0.83% |
| PFM Health Sciences, LP | 3,949,668 | $11,967,000 | 0.46% |
| RTW INVESTMENTS, LP | 4,358,433 | $13,206,000 | 0.34% |
| Omega Fund Management, LLC | 275,513 | $835,000 | 0.27% |
| Sofinnova Investments, Inc. | 981,928 | $2,975,000 | 0.25% |
| Orbimed Advisors | 2,928,900 | $8,875,000 | 0.16% |